Shinobi Therapeutics Inc. has been awarded non-dilutive grant funding of up to $59 million by the Japanese Agency for Medical Research and Development (AMED).
Japan-California startup Shinobi Therapeutics Inc. has emerged from stealth mode with a $51 million series A round to advance its first off-the-shelf induced pluripotent stem cell (iPS)-T cell therapy against glypigan-3 (GPC3)-positive cancers toward the clinic.
Japan-California startup Shinobi Therapeutics Inc. has emerged from stealth mode with a $51 million series A round to advance its first off-the-shelf induced pluripotent stem cell (iPS)-T cell therapy against glypigan-3 (GPC3)-positive cancers toward the clinic.
Shinobi Therapeutics Inc. has closed a $51 million series A financing. The company is developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies.
